

CURRICULUM VITAE

Adrian Franz Ochsenbein

DATE OF BIRTH 6. July 1967
PLACE OF ORIGIN Etziken / SO
NATIONALITY Swiss
MARRIED TO Nadin Ochsenbein-Imhof
CHILDREN David, born 7.9.2001
Noah, born 30.3.2004
PRIVATE ADDRESS Breitenrain 28
3032 Hinterkappelen
Tel. 031 904 03 02

WORKING ADDRESS

Department of Medical Oncology
University Hospital, Inselspital
Freiburgstrasse 10
3010 Bern
Switzerland
Tel: (+41)-31-632-8442 Switzerland
Fax: (+41)-31-632-4119
e-mail: adrian.ochsenbein@insel.ch

Tumor Immunology Laboratory
Department of Clinical Research
University of Bern
Murtenstrasse 31
3010 Berne

Tel: (+41)-31-632-8795

EDUCATION

SCHOOLS 6 years „Primarschule“ Derendingen
2 years „Bezirksschule“ Derendingen/Luterbach
4 ½ years „Kantonsschule“ Solothurn (Matura Typ C)
UNIVERSITY Medicine, University of Bern (1986-1992)
BOARD CERTIFICATE Medical Oncology, FMH (July 2003)
Written and oral exam 2001

POSTGRADUATE TRAINING / FUNCTIONS

Jul 1993 – Oct 1993 Doctor in the army (Lieutenant)
Oct 1993 - Dec 1995 Resident, Internal Medicine, Bürgerspital Solothurn, head: Prof. Dr. H. Bürgi.
Feb 1996 - Oct 1996 Postgraduate Course for Experimental Medicine and Biology
Nov 1996 – Jun 1999 Postdoctoral Research, Institute of Experimental Immunology, University Hospital Zürich, head: Prof. Dr. R.M. Zinkernagel.
Jul 1999- Oct 2001 Resident, Institute of Medical Oncology, University Hospital Berne, head: Prof. Dr. M.F. Fey.
Dec 2001- Dec 2002 Postdoctoral Research, Department of Clinical Research, Fred Hutchinson Cancer Research Centre, Seattle, USA, head: Prof. P.D. Greenberg.
Jan 2003 – Jun 2005 Attending physician, Department of Medical Oncology, University Hospital Berne, head: Prof. Dr. M.F. Fey.

since Jan 2003	Head of the Tumor Immunology Research Group, Department of Clinical Research, University of Berne. (Jan 03 - Dec 07 SNF-Professorship)
Jan 2004-Jul 2005	external Consultant for Medical Oncology Hospital Burgdorf
since Jul 2004	local principal investigator for clinical trials (including trials form collaborative groups such as SAKK and industry) with a focus on thoracic oncology, neuro-oncology, melanoma and immunisation protocols.
Jul 2005-Apr 2011	Senior consultant Medical Oncology University of Bern Head external oncology service of the Canton of Bern External consultant for Medical Oncology Hospital Interlaken Consultant for thoracic oncology, University Hospital of Bern Consultant for neuro-oncology, University Hospital of Bern
Jan 2011-Apr 2011	Deputy chief physician Medical Oncology, University of Bern
since May 2011	Chief physician Medical Oncology, University of Bern

ACADEMICAL DEGREES

PROMOTION DR. MED.: Dec 1992	titel: „ <i>Transcapillary Escape Rate von Albumin, Verhalten von Serumalbumin und Akutphasenproteinen bei akuten Infektionskrankheiten und malignen Erkrankungen</i> “, Prof. Dr. H. Studer, medical director, internal medicine, University Hospital Berne, and Prof. Dr. P. Ballmer, medical director internal medicine, Winterthur.
---------------------------------	---

HABILITATION Aug 2001	Field, experimental immunology, University of Zurich titel: <i>Antigen-dose and -localization drive the immune response.</i>
--------------------------	---

ASSISTANT PROFESSOR Jan 2003	medical faculty University of Bern (SNF-Professor)
---------------------------------	---

UMHABILITATION Nov 2004	Field: medical oncology, University of Bern
----------------------------	---

TITULAR PROFESSOR Feb 2006	Medical Faculty University of Bern
-------------------------------	------------------------------------

ASSOCIATE PROFESSOR Feb 2008	Medical Faculty University of Bern
---------------------------------	------------------------------------

FULL PROFESSOR (EXTRAORDINARIUS) Sep 2011	Medical Faculty University of Bern
---	------------------------------------

AWARDS

Young Investigator Award of the San Salvatore Foundation 2000

Hans Jucker Award for Cancer Research 2000

Pfizer Award for Immunology 2001

SNF-Professorship 2002

Theodor Kocher Award 2005

SAKK / Amgen Award 2009

Wenner Award Swiss Cancer League 2011

PUBLICATIONS

ORIGINAL RESEARCH ARTICLES

Cytotoxic T cells regulate hematopoietic progenitors by promoting cytokine release from bone marrow mesenchymal stromal cells.

Schürch C, Riether C, Ochsenbein A.F.
Cell Stem Cell, 2014; 14:460-72. (IF 2012: 25.3, MR: 1)

Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors.

Lennerz V, Gross S, Gallerani E, Sessa C, Mach N, Boehm S, Hess D, von Boehmer L, Knuth A, Ochsenbein A., Gnad-Vogt U, Zieschang J, Forssmann U, Woelfel T, Kaempgen E.
Cancer Immunology Immunotherapy, 2014; 63:381-94. (IF 2012: 3.6, MR: 0.696)

Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression.

Eisele G, Wick A, Eisele AC, Clement P, Tonn J, Tabatabai G, Ochsenbein A., Schlegel U, Bart Neyns B, Schackert G, Simon M, Nikkhah G, Picard M, Stupp G, Wick W, Weller M.
J Neuro-Oncology, 2014; 117:141-5. (IF 2012: 3.1, MR: 0.714)

TREM-1 deficiency can attenuate disease severity without affecting pathogen clearance.

Weber B, Schuster S, Rihs S, Dickgreber N, Zysset D, Schürch C, Riether C, Siegrist M, Schneider C, Pawelski H, Gurzeler U, Ziltener P, Genitsch V, Tacchini-Cottier F, Ochsenbein A., Hofstetter W, Kopf M, Kaufmann T, Oxenius A, Reith W, Saurer L, Mueller C.
Plos Pathogens, 2014; 10:e1003900 (IF 2012: 8.1, MR: 0.971).

Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon- γ .

Schürch C, Riether C, Amrein MA, Ochsenbein A.F.
J Exp Med. 2013; 210:605-21. (IF 2012: 13.2, MR:0.983).

Long term survival after trimodal therapy in malignant pleural mesothelioma.

Fahrner R, Ochsenbein A., Schmid RA, Carboni GL.
Swiss Med Wkly 2012. 142:w13686. (IF 2012: 1.8, MR: 0.682).

Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05).

Zappa F, Droege C, Betticher D, von Moos R, Bubendorf L, Ochsenbein A., Gautschi O, Oppliger Leibundgut E, Froesch P, Stahel R, Hess T, Rauch D, Schmid P, Mayer M, Crowe S, Brauchli P, Ribi K, Pless M.
Lung Cancer 2012; 78: 239-244. (IF 2012: 3.4, MR: 0.780).

Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with two State of the Art Techniques.

Schoenewolf NL., Dummer R. Michic-Probst D., Moch H. Simcock M, Ochsenbein A., Gillessen S., Schraml P., von Moos R.
Case Rep Oncol. 2012; 5: 280-9.

CD27-signaling increases the frequency of regulatory T cells and promotes tumor growth.

Claus C., Riether C., Schürch C., Matter M.S., T. Hilmenyuk, Ochsenbein A.F.
Cancer Research 2012, 72:3664-76. (IF 2012: 8.7, MR: 0.948).

CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression.

Schürch C, Riether C, Matter MS, Tzankov A, Ochsenbein A.F.
Journal of Clinical Investigation, 2012, 122:624-38. (IF 2012: 12.8, MR: 0.975)

Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK50/07.

Schraml P., Von Teichman A., Mihic-Probst D., Simcock M., Ochsenbein A., Dummer R., Michelin O., Seifert B., Schläppi M., Moch H., von Moos R.
Oncol Rep. 2012; 28: 654-8. (IF 2012: 2.3, MR: 0.440)

Destruction of Lymphoid Organ Architecture and Hepatitis caused by Cytotoxic CD4⁺ T Cells.

Matter MS, Hilmenyuk T, Claus C, Marone R, Schurch C, Tinguely M, Terracciano L, Luther SA and Ochsenbein A.F.
PLoS One. 2011; 6:e24772. (IF 2011: 4.1, MR: 0.867).

First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07).

Von Moos R., Seifert B., Simrock M., Goldinger SM., Ochsenbein A., Michielin O., Cathomas R., Moch H., Schraml PH, Mihic-Probst D. Mamot C., Schönewolf N., Dummer R.
Annals of Oncology 2011;23:531-6. (IF 2011: 6.4, MR: 0.915).

Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials.

Hofer S., Elandt K., Greil R., Hottinger AF., Huber U., Lemka D., Marosi C., Ochsenbein A., Pichler J., Roelcke U., Weder P., Zander T., Wick W., Weller.
Acta Oncol. 2011, 50: 630-5. (IF 2011: 4.1, MR: 0.867).

Quantitative analysis of O6-Methylguanine DNA Methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas.

Ochsenbein A.F., Schubert AD., Vasella E., Mariani L.
Journal of Neuro-Oncology 2011, 103: 343-51. (IF 2011: 3.2, MR: 0.725).

Chronic myelogenous leukemia maintains specific CD8⁺ T cells through IL-7 signalling.

Mumprecht S., Schurch C., Claus C., Ochsenbein A.F.
European Journal of Immunology. 2010, 40:2720-30. (IF 2010: 4.9, MR: 0.842).

Phase III study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.

Stupp R., Hegi ME., Neys B., Goldbrunner R., Schlegel U., Clement P., Grabenbauer GG., Ochsenbein A.F., Schramm J., Dietrich PY., Pietsch T., Tonn JC., Pica A., Hermisson M., Krueger S., Picard M., Weller M.
Journal of Clinical Oncology. 2010, 28: 2712-8. (IF 2010: 18.9, MR: 0.983).

Development of replication-defective lymphocytic choriomeningitis virus vectors for induction of potent CD8⁺ T cell immunity.

Fatz L., Hegazy AN., Bergthaler A, Verschoor A., Claus C., Fernandez M., Gattinoni L., Johnson S., Kreppel F., Kochanek S., van den Broek M., Radbruch A. Lévy F., Lambert PH., Siegrist CA., Restifo NP., Löhning M., Ochsenbein A.F., Nabel GJ, Pinschewer DD.
Nature Medicine. 2010, 16:339-45. (IF 2010: 25.4, MR: 1).

PD-1 signaling on chronic myeloid leukemia-specific T cells results in T cell exhaustion and disease progression.

Mumprecht S., Schurch C., Schwaller J., Solenthaler M., and Ochsenbein A.F.
Blood. 2009, 114: 1528-36. (IF 2009: 10.6, MR: 0.984).

CTL induction by cross-priming is restricted to immunodominant epitopes.

Pavelic V. Matter MS. Mumprecht S. Breyer I. Ochsenbein A.F.
European Journal of Immunology. 2009, 39: 1-13. (IF 2009: 5.2, MR: 0.849)

Defective homing and impaired induction of cytotoxic T cells by BCR/ABL-expressing dendritic cells.

Mumprecht S., Claus C., Pavelic V. Matter MS. Ochsenbein A.F.
Blood. 2009, 113: 4681-9. (IF 2009: 10.6, MR: 0.984).

CD4+ T cell help improves CD8+ T cell memory by retained CD27 expression

Matter MS., Claus C. and Ochsenbein A.F.

European Journal of Immunology. 2008, 38: 1847-56. (IF 2008: 4.9, MR: 0.823)

Decreased tumor surveillance after adoptive immunotherapy.

Matter M., Pavelic V. Pinschewer D., Eschli B., Giroglou T., von Laer D. and Ochsenbein A.F.

Cancer Research. 2007, 67: 7467-7. (IF 2007: 7.7, MR: 0.947)

Elimination of chronic viral infection by blocking CD27 signalling.

Matter M., Odermatt B., Yagita H., Nuoffer J.M, and Ochsenbein A.F.

J. Exp. Med. 2006, 203:2405-8. (IF 2006: 14.5, MR: 0.974)

Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections.

Mumprecht S, Matter M., Pavelic V and Ochsenbein A.F.

Blood. 2006, 108:3406-13. (IF 2006: 10.4, MR: 0.984)

Virus-induced polyclonal B cell activation improves protective cytotoxic T cell memory.

Matter M, Mumprecht S, Pinschewer D.D., Pavelic V, Yagita H, Krautwald S, Borst J., and Ochsenbein A.F.

European Journal of Immunology. 2005, 3229-3239. (IF 2005: 4.9, MR: 0.870)

CD27 expression is required for long-term survival of effector memory CTL in HIV-infected patients.

Ochsenbein, A.F., Brown, M., Baerlocher, G., Landsdrop, P., Riddell, S.R., and Greenberg, P.D. *J Exp Med*. 2004, 1407-1417. (IF 2004: 14.6, MR: 0.986)

Ochsenbein-Imhof N., Ochsenbein A.F., Seifert B., Huch A., Huch R. and Zimmermann R. Quantification of fetomaternal hemorrhage by fluorescence microscopy is equivalent to flow cytometry. *Transfusion*, 2002, 42: 947-53. (IF 2002: 3.7, MR: 0.790)

Leflunomide-mediated suppression of antiviral antibody and T cell responses: differential restoration by uridine.

Pinschewer D.D., Ochsenbein A.F., Fehr T., Zinkernagel R.M.

Transplantation. 2001, 72: 712-719. (IF 2001: 3.6, MR: 0.942)

Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction.

Ochsenbein A.F. Sierra S., Odermatt B. Pericin M. Karrer U., Hermans I., Hemmi S., Hengartner H., Zinkernagel R.M.

Nature. 2001, 411: 712-719. (IF 2001: 32.2, MR: 1)

Rapid peptide turnover and inefficient presentation of exogenous antigen critically limit the activation of self reactive CTL by dendritic cells.

Ludewig B., McCoy K., Pericin M., Ochsenbein A.F., Dumrese T., Odermatt B. Toes R.E. Melief C.J. Hengartner H. Zinkernagel R.M.

J Immunol. 2001, 166: 3678-3687. (IF 2001: 6.5, MR: 0.910)

Protective long-term antibody memory by antigen-driven and T help-dependent differentiation of long-lived memory B cells to short-lived plasma cells independent of secondary lymphoid organs.

Ochsenbein A.F., Pinschewer D.D. Sierra S., Horvath E. Hengartner H. Zinkernagel R.M. *Proc.Natl.Acad.Sci.U.S.A.* 2000, 97: 13263-13268. (IF 2000: 10.5, MR: 0.956)

Lack of CD37 impairs T cell dependent B cell response under suboptimal costimulatory conditions.

Knobeloch, K.P., Wright M.D., Ochsenbein A.F., Liesenfeld O., Löhler J., Zinkernagel R.M., Horvak I., Orinska Z.

Mol.Cell.Biol. 2000, 20:5363-5369. (IF 2000: 7.8, MR: 0.920)

Correlation of T cell independence of antibody responses with antigen dose reaching secondary lymphoid organs.

Ochsenbein A.F., Pinschewer D.D., Odermatt B., Ciurea A., Hengartner H., Zinkernagel R.M.

J. Immunol. 2000, 164: 6296-6302. (IF 2000: 6.5, MR: 0.910)

FTY720 Immunosuppression – impairs effector T cell peripheral homing without affecting induction, expansion and memory.

Pinschewer, D.D., Ochsenbein A.F., Brinkmann V., Hengartner H. and Zinkernagel R.M.
J. Immunol. 2000, 164: 5761-5770. (IF 2000: 6.5, MR: 0.910)

Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells result in severe autoimmune disease.

Ochsenbein A.F.*, Ludewig, B*, Odermatt B., Paulin D., Hengartner H., and Zinkernagel R.M.
J. Exp.Med. 2000, 191: 795-804 (*equal contribution), (IF 2000: 14.6, MR: 0.986)

Viral persistence in vivo through selection of neutralizing antibody-escape variants.

Ciurea, A., Klenerman P., Hunziker L., Horvath E., Senn B.M., Ochsenbein A.F., Hengartner H., and Zinkernagel R.M.
Proc.Natl.Acad.Sci.U.S.A. 2000, 97: 2749-2754. (IF 2000: 10.5, MR: 0.910)

Control of early viral and bacterial distribution and disease by natural antibodies.

Ochsenbein, A.F., Fehr T., Lutz C., Suter M., Brombacher F., Hengartner H., and Zinkernagel R.M.
Science 1999, 286:2156-2159. (IF 1999: 31.9, MR: 1)

Protective T cell-independent antiviral antibody responses are dependent on complement.

Ochsenbein, A.F., Pinschewer D.D., Odermatt B., Carroll M.C., Hengartner H. and Zinkernagel R.M..
J Exp.Med. 1999, 190:1165-1174. (IF 1999: 14.6, MR: 0.986)

Persistence of lymphocytic choriomeningitis virus at very low levels in immune mice.

Ciurea, A., Klenermann P., Hunziker L., Horvath E., Odermatt B., Ochsenbein A.F., Hengartner H., and Zinkernagel R.M.
Proc.Natl.Acad.Sci.U.S.A. 1999, 96:11964-11969. (IF 1999: 10.5, MR: 0.956)

A Btk transgene restores the antiviral TI-2 antibody response of xid mice in a dose-dependent fashion.

Pinschewer, D.D., Ochsenbein A.F., Satterthwaite A.B., Witte O.N., Hengartner H. and Zinkernagel R.M.
Eur.J Immunol. 1999, 29:2981-2987. (IF 1999: 5.0, MR: 0.865)

A comparison of T cell memory against the same antigen induced by virus versus intracellular bacteria.

Ochsenbein, A.F., Karrer U., Klenerman P., Althage A., Ciurea A., Shen H., Miller J.F., Whitton J.L., Hengartner H., and Zinkernagel R.M.
Proc.Natl.Acad.Sci.USA 1999, 96:9293-9298. (IF 1999: 10.5, MR: 0.956)

Immune surveillance against a peripheral solid tumor fails because of immunological ignorance.

Ochsenbein, A.F., P. Klenerman, U. Karrer, B. Ludewig, M. Pericin, Hengartner H. and Zinkernagel R.M.
Proc.Natl.Acad.Sci.USA 1999, 96:2233-2238. (IF 1999: 10.5, MR: 0.956)

T-cell independent IgM and enduring protective IgG antibodies induced by chimeric measles viruses.

Fehr, T., Naim H.Y., Bachmann M.F., Ochsenbein A.F., Spielhofer P., Bucher E., Hengartner H., and Zinkernagel R.M.
Nat.Med. 1998, 4:945-948. (IF 1998: 32.2, MR: 1)

IgD can largely substitute for loss of IgM function in B cells.

Lutz, C., Ledermann B., Kosco-Vilbois M., Ochsenbein A.F., Zinkernagel R.M., Köhler G. and Brombacher F.
Nature 1998, 393:797-801. (IF 1998: 32.2, MR: 1)

Transcapillary escape rate of albumin positively correlates with plasma albumin concentration in acute but not in chronic inflammatory disease.

Ballmer, P.E., Ochsenbein A.F., and Schutz-Hofmann S.

Metabolism 1994, 43:697-705. (IF 1994: 2.1, MR 0.471)

REVIEWS

Dendritic cell-based immunotherapy for myeloid leukemias.

Schürch CM, Riether, Ochsenbein A.F.
Frontiers in Tumor Immunology. 2013, e4:496

Interferons in hematopoiesis and leukemia.

Schürch CM, Riether C, Ochsenbein A.F.
Oncoimmunology 2013, 2:e24572

From “magic bullets” to specific cancer immunotherapy

Riether C., Schürch C, Ochsenbein A.F.
Swiss med Wkly. 2013, 143:w13734 (IF 2012: 1.821, MR: 0.682)

Modulating CD27 signaling to treat cancer.

Riether C., Schurch C., and Ochsenbein A.F.
Oncoimmunology 2012; 1, 1604-1606.

Natural antibodies target virus-antibody complexes to organized lymphoid tissue.

Matter MS., and Ochsenbein A.F.
Autoimmun. Rev. 2008; 76, 480-486.

Early Clinical Trial Experience with Vaccine Therapies in NSCLC

Ho C., Ochsenbein A.F., Gautschi O., Davies A.M.
Clinical Lung Cancer 2008, 20-27.

Immunological ignorance of solid tumors.

Ochsenbein A.F.
Springer Seminars in Immunopathology, 2005 27: 19-35.

Outcome of the antibody response: a question of antigen dose and distribution.

Fehr T. and Ochsenbein A.F.
Trends in Immunology, 2004, 165-166.

Principles of tumor immunosurveillance and their implications for immunotherapy.

Ochsenbein A.F.
Cancer Gene Therapy. 2002, 9: 1043-1055.

Neutralizing antiviral antibody responses.

Zinkernagel R.M., LaMarre A., Ciurea A., Hunziker L., Ochsenbein A.F., McCoy K.D., Fehr T., Bachmann M.F., Kalinke U., Hengartner H.
Adv. Immunol. 2001, 79: 1-53.

Natural antibodies and complement link innate and acquired immunity.

Ochsenbein A.F., Zinkernagel R.M.
Immunol. Today. 2000, 21: 624-630.

Role of dendritic cells in the induction and maintenance of autoimmune diseases.

Ludewig, B., Odermatt B., Ochsenbein A.F., Zinkernagel R.M. and Hengartner H.
Immunol.Rev. 1999, 169:45-54.

NON-PEER REVIEWED ARTIKELES / CASE REPORTS / COMMENTARIES

Bedeutung der Histologie für die Therapie des fortgeschrittenen, nicht-kleinzelligen Bronchuskarzinoms.

Rothschild S., Betticher D.C., Ochsenbein A.F., Stahel R., Bubendorf L., Gugger M., Brutsche M., Pless M., Gautschi O. *Schweiz Med Forum* 2010, 10:384-388.

Monoklonale Antikörpertherapie in der Onkologie

Farese S.A. and Ochsenbein A.F.

Swiss Medical Forum, 2008

Monoklonale Antikörper als therapeutische Substanzen

Ochsenbein A.F.

Swiss Medical Forum, 2008

Extraordinary manifestation of a gastric carcinoma by leptomeningeal carcinomatosis and spinal metastasis.

Cresto N., Barth A, Arnold M., Weimann R., Gschossmann J, Ochsenbein A.F., Kolotas C., Peter HP, Schiemann U.

Medizinische Klinik, 2007, 255-258

Schlaglicht Onkologie 2006: Gezielt gegen das Nierenzellkarzinom?

Ochsenbein A.F.

Swiss Medical Forum 2007, 7, 23-24

Immuntherapien gegen Krebs, Krankheitsabwehr mit Antikörpern, Killerzellen und Co.

Ochsenbein A.F.

Geriatric und Praxis Sonderheft DGHO, 2004, 12-17

Is breast cancer a medical emergency?

Ochsenbein A.F. and Fey M.F.

Commentary. Schweiz.Med.Wochenschr. 2000; 130: 559

A young man with sore throat and infection.

Egger, M., Ochsenbein A.F. and Gerber A.U.

Schweiz.Med.Wochenschr. 1997, 127:861-863.

Acute Phase Reaction.

Imoberdorf, R., Ochsenbein A.F. and Ballmer P.E.

Therapie Woche Schweiz 1996, 11:34-38.

BOOK CHAPTERS

Surf Med, Guidelines Internal Medicine, 2009, Onkologie